The efficacy of chloroquine in treatment of vivax malaria in southern Laos

Completed

• Conditions: Vivax malaria; Infections and Infestations; Malaria

• Registration Number: ISRCTN17027907
• Lead Sponsor: niversity of Oxford (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01-23
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Written informed consent from patient or attending relative
2. Age greater than 1 year old, either sex
3. P. vivax infection (greater than 500 asexual stages/µL)
4. Acute uncomplicated malaria (World Health Organization [WHO] 2000)
5. Axillary temperature greater than 37.5°C
6. No full course of antimalarial treatment in the previous 3 days
7. High probability that patient will be able to complete 42 days follow up

Exclusion Criteria

1. Inability or unwillingness to give informed consent
2. Mixed species malaria infections
3. Severe malaria (WHO, 2000)
4. History of allergy to chloroquine
5. Asymptomatic malaria
6. Low probability of 42 days follow up

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cure rate.<br><br>Outcomes measured daily until parasite clearance and then weekly until 42 days post treatment.

Secondary Outcome Measures

Name	Time	Method
1. Parasite clearance time<br>2. Fever clearance time<br><br>Outcomes measured daily until parasite clearance and then weekly until 42 days post treatment.